文章：

多发性骨髓瘤中的CAR-T疗法：释放未来

CAR T therapies in multiple myeloma: unleashing the future

原文发布日期：2024-03-04 

英文摘要：

In recent years, the field of cancer treatment has witnessed remarkable breakthroughs that have revolutionized the landscape of care for cancer patients. While traditional pillars such as surgery, chemotherapy, and radiation therapy have long been available, a cutting-edge therapeutic approach called CAR T-cell therapy has emerged as a game-changer in treating multiple myeloma (MM). This novel treatment method complements options like autologous stem cell transplants and immunomodulatory medications, such as proteasome inhibitors, by utilizing protein complexes or anti-CD38 antibodies with potent complement-dependent cytotoxic effects. Despite the challenges and obstacles associated with these treatments, the recent approval of the second FDA multiple myeloma CAR T-cell therapy has sparked immense promise in the field. Thus far, the results indicate its potential as a highly effective therapeutic solution. Moreover, ongoing preclinical and clinical trials are exploring the capabilities of CAR T-cells in targeting specific antigens on myeloma cells, offering hope for patients with relapsed/refractory MM (RRMM). These advancements have shown the potential for CAR T cell-based medicines or combination therapies to elicit greater treatment responses and minimize side effects. In this context, it is crucial to delve into the history and functions of CAR T-cells while acknowledging their limitations. We can strategize and develop innovative approaches to overcome these barriers by understanding their challenges. This article aims to provide insights into the application of CAR T-cells in treating MM, shedding light on their potential, limitations, and strategies employed to enhance their efficacy. 

摘要翻译：

近年来，癌症治疗领域取得了显著突破，彻底改变了癌症患者的治疗格局。尽管手术、化疗和放射治疗等传统支柱疗法长期存在，但一种名为CAR T细胞疗法的前沿治疗方法已成为多发性骨髓瘤（MM）治疗领域的颠覆性突破。这种新型治疗方法通过利用具有强效补体依赖性细胞毒性作用的蛋白复合物或抗CD38抗体，与自体干细胞移植和免疫调节药物（如蛋白酶体抑制剂）等治疗方案形成互补。尽管这些治疗手段面临诸多挑战与障碍，美国FDA近期批准的第二款多发性骨髓瘤CAR T细胞疗法为该领域带来了巨大希望。目前结果显示，该疗法有望成为高效治疗方案。此外，正在进行的临床前和临床试验正在探索CAR T细胞靶向骨髓瘤细胞特定抗原的能力，为复发/难治性多发性骨髓瘤（RRMM）患者带来新希望。这些进展表明，基于CAR T细胞的药物或联合疗法有望引发更强的治疗反应并减少副作用。在此背景下，深入探讨CAR T细胞的发展历程和功能并认识其局限性至关重要。通过了解这些挑战，我们可以制定策略并开发创新方法来突破障碍。本文旨在深入解析CAR T细胞在多发性骨髓瘤治疗中的应用，阐明其潜力、局限性以及提升疗效的策略。

原文链接：

CAR T therapies in multiple myeloma: unleashing the future